An evaluation of estrus synchronization programs in reproductive management of dairy herds.
The objectives of this experiment were to evaluate the effect of various estrus synchronization programs on estrus detection rate (EDR) and pregnancy rate (PR) in lactating cows. Spring-calving, lactating dairy cows (n = 3,096) were allocated to one of six treatments: 1) PG (n = 514), estrus detection for 10 d before the onset of the breeding season (BS), cows detected in estrus received PGF2 alpha (PGF) 8 d after estrus, and all cows to be bred by d 11 of BS; 2) PG+EBZ (n = 510), as in PG plus cows treated with PGF received 1 mg of estradiol benzoate 48 h later; 3) C (n = 522), progestogen (controlled intravaginal drug release; CIDR) inserted per vaginum 10 d before BS for 8 d, PGF treatment on the day before CIDR removal, and AI within 6 d after CIDR withdrawal; 4) C+EBZ (n = 520), as in C, plus 10 mg of estradiol benzoate 10 d before BS; 5) C+BUS (n = 517), as in C plus 10 micrograms of buserelin on the day of CIDR insertion; or 6) CON (n = 513), no treatment, and a 32-d period of AI. Relative to other CIDR-treated groups, estradiol benzoate at the time of CIDR insertion reduced (P < .05) the EDR (C, 85.0%;C+EBZ, 75.9%; C+BUS, 88.5%). The PR to first AI was reduced (P < .05) by C compared with other treatments (PG, 60.9%; PG+EBZ, 57.2%; C, 46.6%; C+EBZ, 60.5%; C+BUS, 57.9%; CON, 60.1%). The interval from the onset of BS to AI and pregnancy was reduced (P < .05) by up to 9 d by estrus synchronization relative to controls (PG, 5.5 +/- .2 d; PG+EBZ, 5.2 +/- .2 d; C 1.7 +/- .1 d; C+EBZ, 2.3 +/- .1 d; C+BUS, 106 +/- .04d, CON, 10.4 +/- .3 d). In conclusion an 8-d progestogen-buserelin-PGF treatment resulted in the best overall estrus detection and pregnancy rates, which would be beneficial to a compact calving program.
Ryan
D P
DP
Department of Dairy Husbandry, Teagasc, Fermoy, Co. Cork, Ireland.
Snijders
S
S
Yaakub
H
H
O'Farrell
K J
KJ
D000282:Administration, Intravaginal; D000822:Animal Husbandry / Q000379:methods* / Q000592:standards; D000818:Animals; D002064:Buserelin / Q000008:administration & dosage / Q000494:pharmacology; D002417:Cattle / Q000097:blood / Q000502:physiology*; D003612:Dairying / Q000379:methods* / Q000592:standards; D015237:Dinoprost / Q000008:administration & dosage / Q000494:pharmacology; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000494:pharmacology; D004971:Estrus / Q000187:drug effects / Q000502:physiology*; D004973:Estrus Synchronization / Q000502:physiology*; D005260:Female; D007774:Lactation / Q000502:physiology; D011247:Pregnancy; D018873:Pregnancy Rate; D011374:Progesterone / Q000097:blood; D011372:Progestins / Q000008:administration & dosage / Q000494:pharmacology; D015397:Program Evaluation
D011372:Progestins; D011374:Progesterone; D004958:Estradiol; D015237:Dinoprost; D002064:Buserelin